These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7507404

  • 1. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
    Sotos GA, Grogan L, Allegra CJ.
    Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM.
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
    [Abstract] [Full Text] [Related]

  • 4. Where do we stand with 5-fluorouracil?
    Schmoll HJ, Büchele T, Grothey A, Dempke W.
    Semin Oncol; 1999 Dec; 26(6):589-605. PubMed ID: 10606252
    [Abstract] [Full Text] [Related]

  • 5. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R.
    Cancer; 1993 Mar 01; 71(5):1875-81. PubMed ID: 8448752
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A, Hudes GR, Greene F, LaCreta FP, Brennan J, O'Dwyer PJ.
    Invest New Drugs; 1997 Oct 15; 15(2):139-45. PubMed ID: 9220293
    [Abstract] [Full Text] [Related]

  • 9. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK.
    J Clin Oncol; 1989 Oct 15; 7(10):1407-18. PubMed ID: 2476530
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    Köhne CH, Wilke H, Schöffski P, Schmoll HJ.
    J Infus Chemother; 1996 Oct 15; 6(4):206-10. PubMed ID: 9229317
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE, Schneider A, Martin DS.
    Cancer Invest; 1990 Oct 15; 8(2):263-4. PubMed ID: 2400946
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.